0001213900-25-125478.txt : 20251223 0001213900-25-125478.hdr.sgml : 20251223 20251223172025 ACCESSION NUMBER: 0001213900-25-125478 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251223 DATE AS OF CHANGE: 20251223 EFFECTIVENESS DATE: 20251223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Myrtelle Inc. CENTRAL INDEX KEY: 0001868532 ORGANIZATION NAME: EIN: 853809400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-568043 FILM NUMBER: 251601761 BUSINESS ADDRESS: STREET 1: 17 STATE STREET FLOOR 3 STREET 2: SUITE 350 CITY: NEW YORK STATE: NY ZIP: 10004 BUSINESS PHONE: (917) 929-1005 MAIL ADDRESS: STREET 1: 17 STATE STREET FLOOR 3 STREET 2: SUITE 350 CITY: NEW YORK STATE: NY ZIP: 10004 FORMER COMPANY: FORMER CONFORMED NAME: Myrtelle LLC DATE OF NAME CHANGE: 20210621 D 1 primary_doc.xml X0708 D LIVE 0001868532 Myrtelle Inc. 17 STATE STREET FL3, SUITE 350 NEW YORK NY NEW YORK 10004 (781) 621-2381 DELAWARE None Myrtelle LLC Corporation true 2021 Adrian Stecyk 17 State Street FL3, Suite 350 New York NY NEW YORK 10004 Executive Officer Director Chrystyna Bedrij 17 State Street FL3, Suite 350 New York NY NEW YORK 10004 Director Laurie Platek 17 State Street FL3, Suite 350 New York NY NEW YORK 10004 Director Debra Yu 17 State Street FL3, Suite 350 New York NY NEW YORK 10004 Director Michael Muhonen 17 State Street FL3, Suite 350 New York NY NEW YORK 10004 Director Thomas Barton 17 State Street FL3, Suite 350 New York NY NEW YORK 10004 Director Biotechnology Decline to Disclose 06b false 2025-12-11 false true true Exchanging Convertible Notes for Series B-2 Preferred Stock false 25000 55162634 30531749 24630885 Single private offering of Series B-2 Preferred Stock for cash and conversion of outstanding convertible notes (incl. interest). To date, $30,531,749 sold: ~$5,369,115 cash; ~$25,162,634 converted. false 21 0 0 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false Myrtelle Inc. /s/ Adrian Stecyk Adrian Stecyk Chief Executive Officer and Director 2025-12-23